| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 85 | 2026 | 329 | 17.410 |
Why?
|
| Graft Rejection | 73 | 2024 | 302 | 10.230 |
Why?
|
| Graft Survival | 40 | 2024 | 297 | 5.060 |
Why?
|
| T-Lymphocytes, Regulatory | 13 | 2026 | 219 | 3.820 |
Why?
|
| Heart Transplantation | 35 | 2020 | 176 | 3.680 |
Why?
|
| Immunosuppressive Agents | 35 | 2022 | 381 | 3.640 |
Why?
|
| BK Virus | 8 | 2024 | 23 | 3.020 |
Why?
|
| Organ Transplantation | 12 | 2024 | 57 | 3.020 |
Why?
|
| Kidney Failure, Chronic | 13 | 2024 | 205 | 2.630 |
Why?
|
| Polyomavirus Infections | 7 | 2024 | 45 | 2.400 |
Why?
|
| Viremia | 6 | 2024 | 44 | 1.820 |
Why?
|
| Immunoconjugates | 29 | 2013 | 93 | 1.810 |
Why?
|
| HLA Antigens | 11 | 2021 | 63 | 1.750 |
Why?
|
| Facial Transplantation | 7 | 2021 | 8 | 1.550 |
Why?
|
| Transplantation | 4 | 2019 | 11 | 1.520 |
Why?
|
| Immune Tolerance | 17 | 2020 | 181 | 1.510 |
Why?
|
| Kidney | 15 | 2024 | 455 | 1.500 |
Why?
|
| T-Lymphocytes | 32 | 2024 | 1019 | 1.480 |
Why?
|
| Tumor Virus Infections | 5 | 2024 | 36 | 1.410 |
Why?
|
| Isoantibodies | 9 | 2024 | 35 | 1.400 |
Why?
|
| Allografts | 14 | 2020 | 47 | 1.310 |
Why?
|
| CD28 Antigens | 19 | 2013 | 60 | 1.300 |
Why?
|
| B7-1 Antigen | 22 | 2012 | 74 | 1.300 |
Why?
|
| Humans | 130 | 2026 | 64283 | 1.240 |
Why?
|
| Antiviral Agents | 7 | 2018 | 329 | 1.220 |
Why?
|
| Dendritic Cells | 5 | 2019 | 529 | 1.150 |
Why?
|
| Tissue Donors | 13 | 2021 | 154 | 1.110 |
Why?
|
| Postoperative Complications | 11 | 2024 | 1301 | 1.100 |
Why?
|
| Transplantation, Homologous | 24 | 2023 | 249 | 1.050 |
Why?
|
| Reperfusion Injury | 5 | 2020 | 56 | 1.010 |
Why?
|
| Lipoproteins, HDL | 3 | 2016 | 36 | 0.970 |
Why?
|
| Antigens, Differentiation | 26 | 2007 | 141 | 0.870 |
Why?
|
| Apolipoproteins | 2 | 2016 | 14 | 0.850 |
Why?
|
| Male | 78 | 2026 | 30322 | 0.850 |
Why?
|
| Middle Aged | 52 | 2024 | 17921 | 0.850 |
Why?
|
| Histocompatibility Testing | 7 | 2021 | 32 | 0.840 |
Why?
|
| Female | 66 | 2026 | 33382 | 0.820 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2024 | 102 | 0.780 |
Why?
|
| Plasmapheresis | 4 | 2024 | 17 | 0.780 |
Why?
|
| Th2 Cells | 9 | 2018 | 98 | 0.770 |
Why?
|
| Abatacept | 30 | 2021 | 66 | 0.730 |
Why?
|
| Interleukin-6 | 5 | 2017 | 325 | 0.730 |
Why?
|
| Transplant Recipients | 7 | 2026 | 37 | 0.730 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2022 | 245 | 0.730 |
Why?
|
| Histocompatibility | 3 | 2018 | 8 | 0.710 |
Why?
|
| Antigens, CD | 31 | 2011 | 348 | 0.710 |
Why?
|
| Magnesium | 2 | 2022 | 55 | 0.700 |
Why?
|
| Adult | 42 | 2024 | 17134 | 0.690 |
Why?
|
| Immunoglobulins, Intravenous | 3 | 2022 | 34 | 0.690 |
Why?
|
| Anti-Infective Agents | 2 | 2014 | 150 | 0.690 |
Why?
|
| Magnesium Deficiency | 1 | 2020 | 3 | 0.680 |
Why?
|
| Animals | 78 | 2024 | 20967 | 0.680 |
Why?
|
| HMGB1 Protein | 2 | 2020 | 26 | 0.650 |
Why?
|
| Living Donors | 4 | 2018 | 78 | 0.650 |
Why?
|
| Biopsy | 10 | 2019 | 449 | 0.650 |
Why?
|
| Antibodies, Monoclonal | 15 | 2013 | 870 | 0.640 |
Why?
|
| Tissue and Organ Procurement | 2 | 2019 | 44 | 0.640 |
Why?
|
| Transplants | 1 | 2019 | 9 | 0.630 |
Why?
|
| Calcineurin Inhibitors | 2 | 2013 | 23 | 0.630 |
Why?
|
| Lymphocyte Activation | 15 | 2021 | 761 | 0.620 |
Why?
|
| Apolipoprotein L1 | 2 | 2017 | 6 | 0.610 |
Why?
|
| Biomarkers | 13 | 2021 | 1431 | 0.600 |
Why?
|
| Rats, Inbred Lew | 29 | 2010 | 106 | 0.600 |
Why?
|
| Sialic Acid Binding Immunoglobulin-like Lectins | 1 | 2019 | 3 | 0.600 |
Why?
|
| Treatment Outcome | 21 | 2024 | 5696 | 0.590 |
Why?
|
| Rats | 39 | 2021 | 2005 | 0.590 |
Why?
|
| Immune System | 2 | 2019 | 131 | 0.580 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2019 | 41 | 0.570 |
Why?
|
| Kidney Diseases | 6 | 2020 | 180 | 0.560 |
Why?
|
| Diarrhea | 1 | 2017 | 76 | 0.520 |
Why?
|
| Anemia | 3 | 2008 | 128 | 0.500 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2016 | 32 | 0.500 |
Why?
|
| Hemodiafiltration | 1 | 2016 | 3 | 0.500 |
Why?
|
| Biological Products | 1 | 2018 | 99 | 0.490 |
Why?
|
| Lung Transplantation | 4 | 2021 | 74 | 0.490 |
Why?
|
| Renal Replacement Therapy | 1 | 2016 | 23 | 0.480 |
Why?
|
| Crime | 1 | 2016 | 57 | 0.480 |
Why?
|
| Programmed Cell Death 1 Receptor | 4 | 2012 | 62 | 0.480 |
Why?
|
| Teriparatide | 1 | 2015 | 6 | 0.480 |
Why?
|
| Parathyroidectomy | 1 | 2015 | 7 | 0.470 |
Why?
|
| Hypoparathyroidism | 1 | 2015 | 7 | 0.470 |
Why?
|
| Time Factors | 20 | 2020 | 3725 | 0.470 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 163 | 0.470 |
Why?
|
| Bone Density Conservation Agents | 1 | 2015 | 44 | 0.460 |
Why?
|
| Neoplasms | 2 | 2024 | 1393 | 0.450 |
Why?
|
| Transplantation Tolerance | 5 | 2022 | 69 | 0.450 |
Why?
|
| Retrospective Studies | 19 | 2024 | 6740 | 0.450 |
Why?
|
| Membrane Proteins | 4 | 2021 | 909 | 0.450 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2014 | 147 | 0.440 |
Why?
|
| CTLA-4 Antigen | 27 | 2021 | 73 | 0.440 |
Why?
|
| Cell Adhesion Molecules | 1 | 2015 | 92 | 0.440 |
Why?
|
| Levofloxacin | 2 | 2014 | 13 | 0.440 |
Why?
|
| Genetic Variation | 1 | 2017 | 387 | 0.440 |
Why?
|
| Lectins, C-Type | 1 | 2015 | 89 | 0.440 |
Why?
|
| Desensitization, Immunologic | 1 | 2014 | 13 | 0.430 |
Why?
|
| Prospective Studies | 16 | 2024 | 3318 | 0.430 |
Why?
|
| Thymus Gland | 5 | 2012 | 237 | 0.430 |
Why?
|
| Aged | 25 | 2024 | 14662 | 0.420 |
Why?
|
| Complement System Proteins | 1 | 2014 | 105 | 0.410 |
Why?
|
| Isoantigens | 8 | 2022 | 72 | 0.400 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 705 | 0.400 |
Why?
|
| Prognosis | 8 | 2024 | 1769 | 0.400 |
Why?
|
| Autoantibodies | 3 | 2021 | 184 | 0.390 |
Why?
|
| Fluoroquinolones | 2 | 2010 | 34 | 0.380 |
Why?
|
| Virus Activation | 2 | 2017 | 24 | 0.380 |
Why?
|
| Receptors, Cell Surface | 1 | 2015 | 430 | 0.380 |
Why?
|
| Immunologic Factors | 3 | 2019 | 109 | 0.380 |
Why?
|
| Acute Disease | 11 | 2021 | 671 | 0.380 |
Why?
|
| Membrane Glycoproteins | 10 | 2011 | 671 | 0.380 |
Why?
|
| CD4-Positive T-Lymphocytes | 9 | 2017 | 645 | 0.380 |
Why?
|
| Atovaquone | 1 | 2012 | 5 | 0.370 |
Why?
|
| Sepsis | 1 | 2016 | 290 | 0.370 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2012 | 10 | 0.370 |
Why?
|
| Pneumocystis carinii | 1 | 2012 | 8 | 0.370 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2012 | 19 | 0.370 |
Why?
|
| Gene Expression Profiling | 4 | 2026 | 783 | 0.370 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2012 | 37 | 0.370 |
Why?
|
| Dyslipidemias | 1 | 2012 | 37 | 0.370 |
Why?
|
| Mice | 30 | 2021 | 11004 | 0.370 |
Why?
|
| Apoptosis Regulatory Proteins | 3 | 2011 | 151 | 0.370 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2024 | 248 | 0.360 |
Why?
|
| Risk Factors | 13 | 2024 | 5341 | 0.360 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 800 | 0.350 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 708 | 0.350 |
Why?
|
| Coronary Artery Disease | 4 | 2024 | 320 | 0.350 |
Why?
|
| Hypophosphatemia | 1 | 2011 | 7 | 0.340 |
Why?
|
| Chronic Disease | 12 | 2017 | 756 | 0.340 |
Why?
|
| Renal Insufficiency | 1 | 2011 | 67 | 0.330 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2011 | 108 | 0.330 |
Why?
|
| Clone Cells | 4 | 2009 | 116 | 0.330 |
Why?
|
| Phosphates | 1 | 2011 | 93 | 0.330 |
Why?
|
| Bone Marrow Diseases | 1 | 2010 | 14 | 0.320 |
Why?
|
| Edema | 1 | 2010 | 42 | 0.320 |
Why?
|
| Th1 Cells | 6 | 2016 | 173 | 0.320 |
Why?
|
| Kidney Neoplasms | 1 | 2011 | 166 | 0.310 |
Why?
|
| Models, Immunological | 4 | 2018 | 86 | 0.310 |
Why?
|
| RNA, Messenger | 3 | 2015 | 1552 | 0.310 |
Why?
|
| Double-Blind Method | 3 | 2024 | 744 | 0.310 |
Why?
|
| Mortality | 1 | 2010 | 161 | 0.300 |
Why?
|
| Risk Assessment | 5 | 2019 | 2048 | 0.300 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2024 | 147 | 0.300 |
Why?
|
| Signal Transduction | 8 | 2024 | 3070 | 0.290 |
Why?
|
| Mice, Inbred BALB C | 7 | 2020 | 891 | 0.290 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2019 | 216 | 0.290 |
Why?
|
| Practice Guidelines as Topic | 3 | 2018 | 726 | 0.280 |
Why?
|
| Glomerular Filtration Rate | 5 | 2024 | 120 | 0.270 |
Why?
|
| Follow-Up Studies | 11 | 2024 | 2482 | 0.270 |
Why?
|
| Mice, Inbred C57BL | 13 | 2020 | 3450 | 0.260 |
Why?
|
| Antibodies | 5 | 2021 | 186 | 0.260 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2017 | 74 | 0.260 |
Why?
|
| Antigens, Surface | 1 | 2008 | 199 | 0.260 |
Why?
|
| Platelet-Derived Growth Factor | 2 | 2016 | 21 | 0.260 |
Why?
|
| Rituximab | 2 | 2019 | 89 | 0.250 |
Why?
|
| Hepatitis C, Chronic | 2 | 2018 | 89 | 0.250 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2016 | 125 | 0.250 |
Why?
|
| Preoperative Care | 2 | 2014 | 199 | 0.250 |
Why?
|
| Histocompatibility Antigens Class II | 7 | 2008 | 182 | 0.240 |
Why?
|
| Creatinine | 4 | 2017 | 133 | 0.240 |
Why?
|
| Predictive Value of Tests | 4 | 2018 | 1105 | 0.230 |
Why?
|
| Vascular Diseases | 2 | 2019 | 82 | 0.230 |
Why?
|
| Hypertension, Malignant | 1 | 2005 | 1 | 0.230 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2005 | 6 | 0.230 |
Why?
|
| Mycophenolic Acid | 2 | 2011 | 68 | 0.230 |
Why?
|
| Glomerulonephritis | 3 | 2014 | 32 | 0.230 |
Why?
|
| Th17 Cells | 2 | 2018 | 62 | 0.230 |
Why?
|
| Interferon-gamma | 6 | 2016 | 576 | 0.230 |
Why?
|
| Inflammation | 3 | 2024 | 1163 | 0.220 |
Why?
|
| Mice, Knockout | 7 | 2013 | 2140 | 0.220 |
Why?
|
| CD40 Ligand | 5 | 2002 | 159 | 0.220 |
Why?
|
| Rats, Inbred WF | 12 | 2003 | 56 | 0.220 |
Why?
|
| Ganciclovir | 1 | 2004 | 18 | 0.220 |
Why?
|
| Antilymphocyte Serum | 3 | 2011 | 22 | 0.220 |
Why?
|
| Single-Cell Analysis | 1 | 2026 | 122 | 0.220 |
Why?
|
| Monocytes | 3 | 2017 | 357 | 0.210 |
Why?
|
| Phenotype | 3 | 2026 | 1223 | 0.210 |
Why?
|
| Cyclosporine | 8 | 2011 | 77 | 0.210 |
Why?
|
| Cytomegalovirus Infections | 1 | 2004 | 68 | 0.210 |
Why?
|
| Nephrotic Syndrome | 1 | 2023 | 7 | 0.210 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2023 | 17 | 0.210 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2017 | 679 | 0.210 |
Why?
|
| Gene Expression | 4 | 2021 | 851 | 0.210 |
Why?
|
| Skin | 3 | 2021 | 386 | 0.200 |
Why?
|
| Cytokines | 12 | 2021 | 945 | 0.200 |
Why?
|
| Boston | 3 | 2014 | 255 | 0.200 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2024 | 51 | 0.200 |
Why?
|
| Inflammation Mediators | 1 | 2024 | 178 | 0.200 |
Why?
|
| Transplantation Conditioning | 3 | 2018 | 102 | 0.200 |
Why?
|
| Interleukin-1beta | 3 | 2014 | 271 | 0.190 |
Why?
|
| Pancreatic Neoplasms | 2 | 2016 | 350 | 0.190 |
Why?
|
| Adenosine Triphosphate | 2 | 2022 | 298 | 0.190 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2024 | 172 | 0.190 |
Why?
|
| Skin Transplantation | 9 | 2014 | 154 | 0.190 |
Why?
|
| Transcriptome | 1 | 2026 | 396 | 0.190 |
Why?
|
| Interleukin-17 | 2 | 2016 | 101 | 0.190 |
Why?
|
| Prevalence | 4 | 2008 | 1407 | 0.190 |
Why?
|
| Histocompatibility Antigens | 4 | 2013 | 105 | 0.180 |
Why?
|
| Disease Models, Animal | 5 | 2021 | 2238 | 0.180 |
Why?
|
| Cells, Cultured | 9 | 2017 | 2177 | 0.180 |
Why?
|
| Nephrosis, Lipoid | 1 | 2021 | 7 | 0.180 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2015 | 215 | 0.180 |
Why?
|
| Rats, Inbred F344 | 6 | 2010 | 56 | 0.180 |
Why?
|
| Composite Tissue Allografts | 1 | 2021 | 1 | 0.180 |
Why?
|
| Endothelium, Vascular | 2 | 2014 | 176 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2024 | 259 | 0.180 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 14 | 0.180 |
Why?
|
| Gene Expression Regulation | 2 | 2008 | 1622 | 0.170 |
Why?
|
| Viral Load | 2 | 2014 | 233 | 0.170 |
Why?
|
| Genes, MHC Class II | 2 | 2012 | 37 | 0.170 |
Why?
|
| Ultrasonography, Interventional | 2 | 2019 | 116 | 0.170 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2020 | 9 | 0.170 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2011 | 495 | 0.170 |
Why?
|
| Health Equity | 1 | 2021 | 48 | 0.170 |
Why?
|
| Cryopreservation | 2 | 2017 | 30 | 0.160 |
Why?
|
| Calcium Oxalate | 1 | 2020 | 13 | 0.160 |
Why?
|
| Receptors, Immunologic | 1 | 2021 | 179 | 0.160 |
Why?
|
| Sofosbuvir | 2 | 2018 | 19 | 0.160 |
Why?
|
| Transplantation Immunology | 4 | 2008 | 26 | 0.160 |
Why?
|
| Cohort Studies | 7 | 2021 | 2605 | 0.160 |
Why?
|
| Vascularized Composite Allotransplantation | 2 | 2016 | 4 | 0.160 |
Why?
|
| Heart Failure | 2 | 2019 | 926 | 0.150 |
Why?
|
| Obesity | 2 | 2017 | 1248 | 0.150 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2021 | 291 | 0.150 |
Why?
|
| Cell Proliferation | 4 | 2016 | 1002 | 0.150 |
Why?
|
| Face | 1 | 2019 | 36 | 0.150 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2016 | 174 | 0.150 |
Why?
|
| B-Lymphocytes | 2 | 2019 | 572 | 0.150 |
Why?
|
| Fluorocarbons | 1 | 2019 | 44 | 0.150 |
Why?
|
| Antigen Presentation | 1 | 2021 | 241 | 0.150 |
Why?
|
| B-Lymphocytes, Regulatory | 1 | 2019 | 5 | 0.150 |
Why?
|
| Waiting Lists | 1 | 2019 | 56 | 0.150 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2013 | 617 | 0.150 |
Why?
|
| Skin Neoplasms | 1 | 2024 | 410 | 0.150 |
Why?
|
| DNA, Viral | 3 | 2017 | 234 | 0.150 |
Why?
|
| Cell Movement | 2 | 2018 | 466 | 0.150 |
Why?
|
| Immunity, Cellular | 4 | 2014 | 178 | 0.150 |
Why?
|
| Granzymes | 2 | 2017 | 22 | 0.150 |
Why?
|
| Microscopy, Electron | 3 | 2015 | 251 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2016 | 210 | 0.140 |
Why?
|
| Receptors, Purinergic P2X7 | 1 | 2018 | 9 | 0.140 |
Why?
|
| Lipids | 1 | 2021 | 319 | 0.140 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2018 | 15 | 0.140 |
Why?
|
| Autoimmunity | 2 | 2019 | 240 | 0.140 |
Why?
|
| Acute Kidney Injury | 1 | 2020 | 142 | 0.140 |
Why?
|
| Peptides | 3 | 2011 | 590 | 0.140 |
Why?
|
| Antigens, CD1 | 1 | 2018 | 41 | 0.140 |
Why?
|
| Health Facilities | 1 | 2018 | 43 | 0.140 |
Why?
|
| Obesity Management | 1 | 2017 | 3 | 0.140 |
Why?
|
| Clinical Protocols | 1 | 2018 | 135 | 0.130 |
Why?
|
| United States | 7 | 2021 | 7923 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor C | 2 | 2019 | 21 | 0.130 |
Why?
|
| Killer Cells, Natural | 1 | 2019 | 219 | 0.130 |
Why?
|
| Health Care Surveys | 1 | 2018 | 289 | 0.130 |
Why?
|
| Regenerative Medicine | 1 | 2017 | 20 | 0.130 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2017 | 42 | 0.130 |
Why?
|
| Organ Preservation | 1 | 2017 | 21 | 0.130 |
Why?
|
| Organ Culture Techniques | 1 | 2017 | 70 | 0.130 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 4 | 2000 | 59 | 0.130 |
Why?
|
| Antibodies, Blocking | 3 | 2013 | 39 | 0.130 |
Why?
|
| Apoptosis | 5 | 2017 | 1095 | 0.130 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2017 | 60 | 0.130 |
Why?
|
| Quality Assurance, Health Care | 1 | 2019 | 254 | 0.130 |
Why?
|
| Cause of Death | 1 | 2018 | 222 | 0.130 |
Why?
|
| Flow Cytometry | 4 | 2012 | 668 | 0.130 |
Why?
|
| House Calls | 1 | 2017 | 23 | 0.130 |
Why?
|
| Kidney Function Tests | 3 | 2024 | 37 | 0.130 |
Why?
|
| Exosomes | 1 | 2017 | 52 | 0.130 |
Why?
|
| Disease Progression | 6 | 2017 | 1176 | 0.130 |
Why?
|
| Glycoproteins | 1 | 2018 | 189 | 0.130 |
Why?
|
| Bariatric Surgery | 1 | 2017 | 63 | 0.130 |
Why?
|
| Young Adult | 3 | 2019 | 4781 | 0.130 |
Why?
|
| Primary Graft Dysfunction | 1 | 2016 | 5 | 0.130 |
Why?
|
| Simeprevir | 1 | 2016 | 5 | 0.130 |
Why?
|
| Metabolomics | 1 | 2017 | 57 | 0.130 |
Why?
|
| Congresses as Topic | 1 | 2017 | 79 | 0.120 |
Why?
|
| Ribavirin | 1 | 2016 | 23 | 0.120 |
Why?
|
| Glycolysis | 1 | 2016 | 57 | 0.120 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2018 | 260 | 0.120 |
Why?
|
| Incidence | 4 | 2015 | 1385 | 0.120 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2011 | 182 | 0.120 |
Why?
|
| Receptors, Interleukin-2 | 2 | 2011 | 71 | 0.120 |
Why?
|
| Biosensing Techniques | 1 | 2017 | 128 | 0.120 |
Why?
|
| Lung Diseases | 1 | 2017 | 183 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2014 | 423 | 0.120 |
Why?
|
| Nephritis | 1 | 2015 | 11 | 0.110 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2015 | 10 | 0.110 |
Why?
|
| Registries | 1 | 2019 | 885 | 0.110 |
Why?
|
| Toll-Like Receptor 8 | 1 | 2015 | 50 | 0.110 |
Why?
|
| Imidazoles | 1 | 2015 | 84 | 0.110 |
Why?
|
| Cholesterol | 1 | 2016 | 260 | 0.110 |
Why?
|
| CD40 Antigens | 2 | 2013 | 60 | 0.110 |
Why?
|
| Immediate-Early Proteins | 1 | 2015 | 45 | 0.110 |
Why?
|
| Toll-Like Receptors | 1 | 2016 | 433 | 0.110 |
Why?
|
| Immunity, Innate | 2 | 2019 | 803 | 0.110 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2015 | 104 | 0.110 |
Why?
|
| Patient Compliance | 1 | 2017 | 362 | 0.110 |
Why?
|
| Liver Cirrhosis | 1 | 2016 | 180 | 0.110 |
Why?
|
| Heart | 1 | 2016 | 288 | 0.110 |
Why?
|
| Kidney Glomerulus | 1 | 2014 | 23 | 0.110 |
Why?
|
| Health Personnel | 1 | 2018 | 389 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2011 | 629 | 0.110 |
Why?
|
| Graft vs Host Reaction | 1 | 2014 | 7 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 58 | 0.110 |
Why?
|
| Receptors, Purinergic | 1 | 2014 | 6 | 0.110 |
Why?
|
| Cell Differentiation | 2 | 2011 | 1366 | 0.110 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 192 | 0.110 |
Why?
|
| CD58 Antigens | 1 | 2013 | 2 | 0.100 |
Why?
|
| Survival Rate | 3 | 2020 | 859 | 0.100 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 202 | 0.100 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2013 | 14 | 0.100 |
Why?
|
| Janus Kinases | 1 | 2013 | 16 | 0.100 |
Why?
|
| Immunohistochemistry | 5 | 2021 | 901 | 0.100 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 266 | 0.100 |
Why?
|
| Jagged-2 Protein | 1 | 2013 | 2 | 0.100 |
Why?
|
| Communicable Diseases | 1 | 2014 | 91 | 0.100 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 375 | 0.100 |
Why?
|
| Cell Line | 5 | 2011 | 2057 | 0.100 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 478 | 0.100 |
Why?
|
| Protein Kinase C | 1 | 2013 | 103 | 0.100 |
Why?
|
| Cell Line, Tumor | 5 | 2016 | 1496 | 0.100 |
Why?
|
| CD4 Antigens | 4 | 2011 | 151 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2015 | 220 | 0.100 |
Why?
|
| Receptors, Nicotinic | 1 | 2013 | 67 | 0.100 |
Why?
|
| Nephrology | 2 | 2017 | 17 | 0.100 |
Why?
|
| Lymphocyte Culture Test, Mixed | 4 | 2007 | 35 | 0.100 |
Why?
|
| Macrophage Activation | 1 | 2013 | 119 | 0.100 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2013 | 14 | 0.100 |
Why?
|
| Linear Models | 1 | 2014 | 408 | 0.100 |
Why?
|
| Delivery of Health Care | 1 | 2017 | 437 | 0.100 |
Why?
|
| Mice, Mutant Strains | 1 | 2013 | 302 | 0.100 |
Why?
|
| Tacrolimus | 3 | 2011 | 64 | 0.100 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2013 | 129 | 0.090 |
Why?
|
| Down-Regulation | 2 | 2011 | 320 | 0.090 |
Why?
|
| Algorithms | 1 | 2017 | 1029 | 0.090 |
Why?
|
| Hypolipidemic Agents | 1 | 2012 | 25 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 930 | 0.090 |
Why?
|
| Mutation | 3 | 2018 | 2633 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2015 | 1131 | 0.090 |
Why?
|
| Global Health | 2 | 2016 | 183 | 0.090 |
Why?
|
| Growth Inhibitors | 1 | 2011 | 26 | 0.090 |
Why?
|
| Lymphocytes | 5 | 2004 | 203 | 0.090 |
Why?
|
| Ureteral Neoplasms | 1 | 2011 | 8 | 0.090 |
Why?
|
| Self Tolerance | 1 | 2011 | 20 | 0.090 |
Why?
|
| Fluorescent Antibody Technique | 4 | 2016 | 235 | 0.090 |
Why?
|
| Calcium Compounds | 1 | 2011 | 5 | 0.090 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 2001 | 145 | 0.090 |
Why?
|
| Acetates | 1 | 2011 | 34 | 0.080 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2011 | 43 | 0.080 |
Why?
|
| Age Factors | 3 | 2011 | 1570 | 0.080 |
Why?
|
| Rats, Wistar | 2 | 2009 | 187 | 0.080 |
Why?
|
| Immunization | 3 | 2003 | 135 | 0.080 |
Why?
|
| Bone Marrow | 1 | 2011 | 175 | 0.080 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2011 | 106 | 0.080 |
Why?
|
| Aorta | 1 | 2010 | 110 | 0.080 |
Why?
|
| Foot | 1 | 2010 | 42 | 0.080 |
Why?
|
| Genotype | 1 | 2012 | 668 | 0.080 |
Why?
|
| Proportional Hazards Models | 3 | 2019 | 735 | 0.080 |
Why?
|
| Hand | 1 | 2010 | 75 | 0.080 |
Why?
|
| Models, Animal | 1 | 2010 | 240 | 0.080 |
Why?
|
| Administration, Oral | 1 | 2011 | 374 | 0.080 |
Why?
|
| Nutrition Surveys | 1 | 2010 | 144 | 0.080 |
Why?
|
| Polysaccharides, Bacterial | 2 | 1999 | 46 | 0.080 |
Why?
|
| Infusions, Intravenous | 1 | 2010 | 176 | 0.080 |
Why?
|
| Recurrence | 2 | 2023 | 652 | 0.080 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 343 | 0.080 |
Why?
|
| Immunophenotyping | 3 | 2017 | 197 | 0.080 |
Why?
|
| Interleukin-23 | 1 | 2009 | 18 | 0.070 |
Why?
|
| Peptide Fragments | 3 | 1999 | 417 | 0.070 |
Why?
|
| Macrophages | 2 | 2013 | 1053 | 0.070 |
Why?
|
| Bone Marrow Transplantation | 2 | 1999 | 140 | 0.070 |
Why?
|
| Surgery, Plastic | 1 | 2008 | 19 | 0.070 |
Why?
|
| Rats, Inbred BN | 8 | 1999 | 26 | 0.070 |
Why?
|
| Endomyocardial Fibrosis | 1 | 2007 | 4 | 0.070 |
Why?
|
| B7-2 Antigen | 4 | 2004 | 32 | 0.070 |
Why?
|
| Antigen-Presenting Cells | 3 | 2011 | 178 | 0.070 |
Why?
|
| Protein Binding | 3 | 2011 | 1619 | 0.070 |
Why?
|
| Pain | 1 | 2010 | 407 | 0.070 |
Why?
|
| Models, Biological | 2 | 2006 | 1187 | 0.070 |
Why?
|
| Mesoderm | 1 | 2007 | 85 | 0.070 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2007 | 6 | 0.070 |
Why?
|
| Simian virus 40 | 1 | 2007 | 17 | 0.060 |
Why?
|
| Body Mass Index | 1 | 2011 | 874 | 0.060 |
Why?
|
| Mycoses | 1 | 2007 | 47 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2012 | 2621 | 0.060 |
Why?
|
| Enzyme Inhibitors | 2 | 2007 | 373 | 0.060 |
Why?
|
| Chimera | 2 | 2004 | 42 | 0.060 |
Why?
|
| Antifungal Agents | 1 | 2007 | 128 | 0.060 |
Why?
|
| Mice, Transgenic | 5 | 2011 | 1297 | 0.060 |
Why?
|
| Polyomavirus | 1 | 2006 | 24 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2020 | 356 | 0.060 |
Why?
|
| Urine | 1 | 2006 | 45 | 0.060 |
Why?
|
| C-Reactive Protein | 1 | 2007 | 166 | 0.060 |
Why?
|
| Postoperative Period | 1 | 2006 | 137 | 0.060 |
Why?
|
| Immunoglobulin G | 6 | 2011 | 463 | 0.060 |
Why?
|
| Endothelial Cells | 1 | 2007 | 193 | 0.060 |
Why?
|
| Interleukins | 2 | 2013 | 80 | 0.060 |
Why?
|
| Renal Dialysis | 1 | 2007 | 195 | 0.060 |
Why?
|
| Phosphotyrosine | 1 | 2005 | 24 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 544 | 0.060 |
Why?
|
| Medicare | 2 | 2021 | 611 | 0.060 |
Why?
|
| Chemokine CCL2 | 2 | 2012 | 57 | 0.060 |
Why?
|
| DNA Helicases | 1 | 2007 | 192 | 0.060 |
Why?
|
| MAP Kinase Signaling System | 2 | 2016 | 231 | 0.060 |
Why?
|
| Hyperhomocysteinemia | 1 | 2004 | 6 | 0.060 |
Why?
|
| Homocysteine | 1 | 2004 | 33 | 0.060 |
Why?
|
| Blotting, Western | 2 | 2016 | 614 | 0.060 |
Why?
|
| DNA Replication | 1 | 2007 | 241 | 0.060 |
Why?
|
| Rats, Inbred Strains | 3 | 2000 | 150 | 0.060 |
Why?
|
| Lymphocyte Count | 2 | 2021 | 73 | 0.050 |
Why?
|
| Comorbidity | 1 | 2008 | 1119 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2005 | 128 | 0.050 |
Why?
|
| Drug Antagonism | 1 | 2004 | 9 | 0.050 |
Why?
|
| Autoimmune Diseases | 2 | 2011 | 233 | 0.050 |
Why?
|
| Erythropoietin | 1 | 2004 | 40 | 0.050 |
Why?
|
| Sclerosis | 1 | 2023 | 10 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2004 | 251 | 0.050 |
Why?
|
| Ligands | 3 | 2011 | 417 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2024 | 129 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 2 | 2011 | 519 | 0.050 |
Why?
|
| Intraoperative Care | 1 | 2003 | 38 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2004 | 143 | 0.050 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2003 | 25 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2003 | 63 | 0.050 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2003 | 109 | 0.050 |
Why?
|
| Postoperative Care | 1 | 2003 | 124 | 0.050 |
Why?
|
| Adoptive Transfer | 4 | 2011 | 149 | 0.050 |
Why?
|
| Child | 2 | 2023 | 4583 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2024 | 220 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 2 | 2007 | 174 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2014 | 1683 | 0.050 |
Why?
|
| Ribonucleases | 1 | 2002 | 33 | 0.050 |
Why?
|
| Hematopoiesis | 2 | 1999 | 125 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2024 | 181 | 0.050 |
Why?
|
| Crosses, Genetic | 1 | 2002 | 110 | 0.050 |
Why?
|
| Stem Cells | 1 | 2004 | 262 | 0.050 |
Why?
|
| Bacterial Vaccines | 2 | 1999 | 81 | 0.050 |
Why?
|
| Antibody Specificity | 1 | 2002 | 102 | 0.050 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 2001 | 10 | 0.050 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2024 | 202 | 0.050 |
Why?
|
| Podocytes | 1 | 2021 | 12 | 0.050 |
Why?
|
| Health Services Accessibility | 1 | 2007 | 575 | 0.040 |
Why?
|
| Cricetinae | 1 | 2002 | 368 | 0.040 |
Why?
|
| Islets of Langerhans Transplantation | 2 | 1999 | 178 | 0.040 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2001 | 18 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2017 | 1020 | 0.040 |
Why?
|
| bcl-X Protein | 2 | 2016 | 23 | 0.040 |
Why?
|
| Proteinuria | 2 | 1997 | 43 | 0.040 |
Why?
|
| B7-H1 Antigen | 2 | 2011 | 59 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 2218 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 788 | 0.040 |
Why?
|
| Cross Reactions | 1 | 2000 | 134 | 0.040 |
Why?
|
| Coronary Disease | 1 | 2001 | 246 | 0.040 |
Why?
|
| DNA Primers | 2 | 2017 | 295 | 0.040 |
Why?
|
| Reoperation | 1 | 2021 | 292 | 0.040 |
Why?
|
| Abscess | 1 | 2000 | 80 | 0.040 |
Why?
|
| Vaccines, Conjugate | 1 | 1999 | 19 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2020 | 94 | 0.040 |
Why?
|
| Rabbits | 2 | 2011 | 333 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2000 | 106 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2002 | 265 | 0.040 |
Why?
|
| Oxides | 1 | 2019 | 36 | 0.040 |
Why?
|
| Ferric Compounds | 1 | 2019 | 44 | 0.040 |
Why?
|
| Microspheres | 1 | 2019 | 57 | 0.040 |
Why?
|
| Porins | 1 | 1999 | 62 | 0.040 |
Why?
|
| Streptococcus agalactiae | 1 | 1999 | 79 | 0.040 |
Why?
|
| Image-Guided Biopsy | 1 | 2019 | 50 | 0.040 |
Why?
|
| Chemokines | 1 | 1999 | 93 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 1999 | 138 | 0.040 |
Why?
|
| Lymphocyte Transfusion | 1 | 1999 | 37 | 0.040 |
Why?
|
| Vimentin | 1 | 2019 | 19 | 0.040 |
Why?
|
| Oligopeptides | 1 | 1999 | 135 | 0.040 |
Why?
|
| Lymphocyte Depletion | 1 | 1999 | 102 | 0.040 |
Why?
|
| Neisseria meningitidis | 1 | 1999 | 78 | 0.040 |
Why?
|
| Antibodies, Bacterial | 1 | 1999 | 182 | 0.040 |
Why?
|
| Iron | 1 | 2019 | 154 | 0.040 |
Why?
|
| Uridine Monophosphate | 1 | 2018 | 9 | 0.040 |
Why?
|
| Fluorenes | 1 | 2018 | 15 | 0.040 |
Why?
|
| Clonal Deletion | 1 | 1998 | 13 | 0.040 |
Why?
|
| Radiation Chimera | 1 | 1998 | 58 | 0.040 |
Why?
|
| Brain Death | 1 | 1998 | 17 | 0.040 |
Why?
|
| Base Sequence | 2 | 2017 | 1335 | 0.040 |
Why?
|
| Research Report | 1 | 2018 | 28 | 0.030 |
Why?
|
| Neurons | 1 | 2004 | 934 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2019 | 141 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 1999 | 230 | 0.030 |
Why?
|
| Endothelins | 1 | 1997 | 3 | 0.030 |
Why?
|
| Risk | 1 | 2019 | 379 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2018 | 56 | 0.030 |
Why?
|
| Chemokine CCL5 | 1 | 1997 | 33 | 0.030 |
Why?
|
| Immunodominant Epitopes | 1 | 1998 | 57 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 1997 | 54 | 0.030 |
Why?
|
| Interleukin-4 | 2 | 2012 | 146 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 458 | 0.030 |
Why?
|
| Immunization, Passive | 1 | 1998 | 96 | 0.030 |
Why?
|
| Serpins | 1 | 2017 | 19 | 0.030 |
Why?
|
| Myosins | 1 | 2019 | 115 | 0.030 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1998 | 112 | 0.030 |
Why?
|
| Tissue Preservation | 1 | 2017 | 5 | 0.030 |
Why?
|
| Cold Temperature | 1 | 1997 | 51 | 0.030 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 1997 | 6 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2017 | 108 | 0.030 |
Why?
|
| Nephrectomy | 1 | 1997 | 93 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2011 | 375 | 0.030 |
Why?
|
| Extracellular Vesicles | 1 | 2017 | 46 | 0.030 |
Why?
|
| Growth Substances | 1 | 1997 | 34 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2018 | 124 | 0.030 |
Why?
|
| Contrast Media | 1 | 2019 | 429 | 0.030 |
Why?
|
| Hepacivirus | 1 | 2018 | 140 | 0.030 |
Why?
|
| Thailand | 1 | 2017 | 98 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2011 | 587 | 0.030 |
Why?
|
| HT29 Cells | 1 | 2016 | 31 | 0.030 |
Why?
|
| Myelin Basic Protein | 1 | 1996 | 21 | 0.030 |
Why?
|
| Pancreatitis, Chronic | 1 | 2016 | 21 | 0.030 |
Why?
|
| Cell Division | 3 | 2004 | 455 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2016 | 52 | 0.030 |
Why?
|
| Community Health Workers | 1 | 2017 | 41 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2017 | 129 | 0.030 |
Why?
|
| Motion | 1 | 2016 | 62 | 0.030 |
Why?
|
| Protease Inhibitors | 1 | 1997 | 106 | 0.030 |
Why?
|
| Forecasting | 1 | 2017 | 233 | 0.030 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2016 | 223 | 0.030 |
Why?
|
| Behavior Therapy | 1 | 2017 | 167 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2021 | 2019 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2017 | 147 | 0.030 |
Why?
|
| Video Recording | 1 | 2016 | 140 | 0.030 |
Why?
|
| Microscopy | 1 | 2016 | 94 | 0.030 |
Why?
|
| Endothelin-1 | 1 | 2015 | 7 | 0.030 |
Why?
|
| Artifacts | 1 | 2016 | 127 | 0.030 |
Why?
|
| Pravastatin | 1 | 2015 | 3 | 0.030 |
Why?
|
| Proteomics | 1 | 2017 | 294 | 0.030 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2016 | 212 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2016 | 209 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2015 | 167 | 0.030 |
Why?
|
| Disease Management | 1 | 2017 | 237 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2017 | 329 | 0.030 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2016 | 351 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 467 | 0.030 |
Why?
|
| Rural Population | 1 | 2017 | 212 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 209 | 0.030 |
Why?
|
| Immunoglobulin M | 3 | 1999 | 115 | 0.030 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 2007 | 50 | 0.030 |
Why?
|
| Length of Stay | 2 | 2011 | 819 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2017 | 340 | 0.030 |
Why?
|
| Diet | 1 | 2017 | 533 | 0.030 |
Why?
|
| Niacin | 1 | 2013 | 4 | 0.030 |
Why?
|
| Medicaid | 1 | 2017 | 362 | 0.030 |
Why?
|
| Antibody Formation | 3 | 1999 | 114 | 0.030 |
Why?
|
| Biological Transport, Active | 1 | 2013 | 37 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2016 | 276 | 0.030 |
Why?
|
| ROC Curve | 1 | 2014 | 288 | 0.030 |
Why?
|
| Chemotaxis | 1 | 2013 | 49 | 0.030 |
Why?
|
| Lipoproteins, LDL | 1 | 2013 | 46 | 0.030 |
Why?
|
| Spleen | 3 | 1999 | 483 | 0.030 |
Why?
|
| Neuroleptic Malignant Syndrome | 1 | 1992 | 2 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 460 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2012 | 72 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1561 | 0.020 |
Why?
|
| Mice, 129 Strain | 1 | 2011 | 41 | 0.020 |
Why?
|
| Yugoslavia | 1 | 2011 | 2 | 0.020 |
Why?
|
| Turkey | 1 | 2011 | 14 | 0.020 |
Why?
|
| Cystoscopy | 1 | 2011 | 17 | 0.020 |
Why?
|
| Germany | 1 | 2011 | 54 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2013 | 471 | 0.020 |
Why?
|
| Cell Polarity | 1 | 2011 | 109 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 109 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2013 | 625 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2011 | 131 | 0.020 |
Why?
|
| Exercise | 1 | 2017 | 954 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 412 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2011 | 517 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2011 | 526 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2011 | 529 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2011 | 189 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2011 | 285 | 0.020 |
Why?
|
| Safety | 1 | 2010 | 145 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 1164 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 358 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 1270 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2007 | 16 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2007 | 60 | 0.020 |
Why?
|
| In Vitro Techniques | 2 | 1999 | 490 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 1272 | 0.020 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2007 | 62 | 0.020 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2007 | 11 | 0.020 |
Why?
|
| Naphthyridines | 1 | 2007 | 6 | 0.020 |
Why?
|
| Ofloxacin | 1 | 2007 | 8 | 0.020 |
Why?
|
| Viral Plaque Assay | 1 | 2007 | 16 | 0.020 |
Why?
|
| Ciprofloxacin | 1 | 2007 | 26 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2007 | 237 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2000 | 1597 | 0.020 |
Why?
|
| Isoxazoles | 1 | 2006 | 14 | 0.020 |
Why?
|
| Organophosphonates | 1 | 2006 | 22 | 0.020 |
Why?
|
| Cytosine | 1 | 2006 | 30 | 0.020 |
Why?
|
| Quinolones | 1 | 2006 | 30 | 0.020 |
Why?
|
| Central Nervous System | 2 | 2000 | 197 | 0.020 |
Why?
|
| Patient Selection | 1 | 2008 | 487 | 0.010 |
Why?
|
| Immunologic Memory | 1 | 2007 | 290 | 0.010 |
Why?
|
| Virus Replication | 1 | 2007 | 324 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 869 | 0.010 |
Why?
|
| Fasting | 1 | 2004 | 51 | 0.010 |
Why?
|
| Cell Separation | 1 | 2004 | 146 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2004 | 239 | 0.010 |
Why?
|
| Inducible T-Cell Co-Stimulator Ligand | 1 | 2003 | 4 | 0.010 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2003 | 5 | 0.010 |
Why?
|
| Receptors, OX40 | 1 | 2003 | 1 | 0.010 |
Why?
|
| Tumor Necrosis Factors | 1 | 2003 | 8 | 0.010 |
Why?
|
| Rats, Nude | 1 | 2003 | 24 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2003 | 47 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 2003 | 37 | 0.010 |
Why?
|
| Cadaver | 1 | 2003 | 129 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2003 | 142 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 2002 | 26 | 0.010 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2001 | 16 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2001 | 49 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2001 | 34 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2002 | 161 | 0.010 |
Why?
|
| Tunica Intima | 1 | 2001 | 15 | 0.010 |
Why?
|
| Carotid Artery Injuries | 1 | 2001 | 12 | 0.010 |
Why?
|
| Catheterization | 1 | 2001 | 113 | 0.010 |
Why?
|
| Fibrosis | 1 | 2001 | 162 | 0.010 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 1 | 2000 | 9 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2001 | 299 | 0.010 |
Why?
|
| Myelin-Associated Glycoprotein | 1 | 2000 | 13 | 0.010 |
Why?
|
| Demyelinating Diseases | 1 | 2000 | 15 | 0.010 |
Why?
|
| Myelin Proteins | 1 | 2000 | 30 | 0.010 |
Why?
|
| Fibrin | 1 | 2000 | 19 | 0.010 |
Why?
|
| Anti-Glomerular Basement Membrane Disease | 1 | 2000 | 8 | 0.010 |
Why?
|
| Basement Membrane | 1 | 2000 | 25 | 0.010 |
Why?
|
| Coronary Vessels | 1 | 2001 | 124 | 0.010 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 1999 | 9 | 0.010 |
Why?
|
| Immunization Schedule | 1 | 1999 | 18 | 0.010 |
Why?
|
| Heme Oxygenase-1 | 1 | 1999 | 20 | 0.010 |
Why?
|
| Perforin | 1 | 1999 | 31 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2000 | 165 | 0.010 |
Why?
|
| Arteriosclerosis | 1 | 1999 | 32 | 0.010 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 1999 | 38 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2001 | 625 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1999 | 176 | 0.010 |
Why?
|
| Mice, Nude | 1 | 1999 | 281 | 0.010 |
Why?
|
| DNA | 1 | 2004 | 844 | 0.010 |
Why?
|
| Whole-Body Irradiation | 1 | 1999 | 33 | 0.010 |
Why?
|
| Thymectomy | 1 | 1999 | 35 | 0.010 |
Why?
|
| Myocardium | 1 | 2001 | 288 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2007 | 2738 | 0.010 |
Why?
|
| Rats, Inbred ACI | 1 | 1998 | 6 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1999 | 192 | 0.010 |
Why?
|
| Serine Endopeptidases | 1 | 1999 | 121 | 0.010 |
Why?
|
| Injections | 1 | 1998 | 82 | 0.010 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 1999 | 201 | 0.010 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 1998 | 43 | 0.010 |
Why?
|
| RNA | 1 | 2001 | 429 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1998 | 119 | 0.010 |
Why?
|
| Neisseria gonorrhoeae | 1 | 1999 | 202 | 0.010 |
Why?
|
| Cell Lineage | 1 | 1998 | 273 | 0.010 |
Why?
|
| Vaccination | 1 | 1999 | 371 | 0.010 |
Why?
|
| Piperidines | 1 | 1997 | 66 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1999 | 487 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2000 | 1999 | 0.010 |
Why?
|
| Ischemia | 1 | 1997 | 196 | 0.010 |
Why?
|
| Brain | 1 | 2004 | 1581 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 1995 | 167 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1999 | 884 | 0.010 |
Why?
|
| Sex Factors | 1 | 1997 | 980 | 0.010 |
Why?
|
| Trifluoperazine | 1 | 1992 | 3 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 1992 | 42 | 0.010 |
Why?
|
| Escherichia coli Infections | 1 | 1992 | 89 | 0.010 |
Why?
|
| Urinary Tract Infections | 1 | 1992 | 93 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1992 | 104 | 0.010 |
Why?
|
| Depressive Disorder | 1 | 1992 | 286 | 0.000 |
Why?
|